BRAF/MEK 抑制剂彻底改变了 BRAF V600E 变异型未分化甲状腺癌 (BRAFv-ATC) 的治疗，为患有这种以前无法治愈的疾病的患者提供了更好的治疗效果。未分化甲状腺癌 (ATC) 约占甲状腺癌相关死亡的一半。它表现为一种快速生长的肿瘤，经常侵入局部区域结构并早期扩散到远处部位；因此，及时诊断、分期和开始治疗对于 ATC 的治疗至关重要。尽管大多数肿瘤学家在实践中都会遇到 ATC 患者，但这种疾病的罕见性使得治疗具有挑战性，特别是因为患有 BRAFv-ATC 的患者不再有令人沮丧的预后。 BRAF/MEK 激酶抑制剂改变了 BRAFv-ATC 的前景和治疗。因此，通过分子分析来识别这些患者至关重要。最近，在 BRAF/MEK 抑制剂的基础上添加免疫疗法以及使用新辅助方法被证明可以进一步改善 BRAFv-ATC 的生存结果。其中许多最新进展尚未纳入当前可用的指南，导致美国各地 BRAFv-ATC 患者的治疗存在差异。随着 BRAFv-ATC 管理日益复杂，本共识声明旨在由专家组制定指导性建议，以促进治疗决策。本共识声明来自 MD 安德森 FAST（促进甲状腺未分化癌专业治疗）小组癌症中心强调，快速识别 BRAF V600E 致病性变异并及时启动序贯治疗对于避免 BRAFv-ATC 患者发病率和死亡率过高至关重要。在过去的十年中，BRAFv-ATC 患者的治疗取得了显着的进展，证明了来自大容量中心的专家达成的共识所达成的这些新的基于证据的建议的合理性。

BRAF/MEK inhibitors revolutionized the treatment of BRAF V600E-variant anaplastic thyroid carcinoma (BRAFv-ATC), offering improved outcomes for patients with this previously incurable disease.Anaplastic thyroid carcinoma (ATC) accounts for approximately half of thyroid cancer-related deaths. It presents as a rapidly growing tumor that often invades locoregional structures and spreads to distant sites early; therefore, prompt diagnosis, staging, and treatment initiation are of the essence in the treatment of ATC. Although most oncologists will encounter a patient with ATC in their practice, the rarity of this disease makes treatment challenging, particularly because those with BRAFv-ATC no longer have a dismal prognosis. BRAF/MEK kinase inhibitors have transformed the outlook and treatment of BRAFv-ATC. Therefore, molecular profiling to identify these patients is critical. More recently, the addition of immunotherapy to BRAF/MEK inhibitors as well as the use of the neoadjuvant approach were shown to further improve survival outcomes in BRAFv-ATC. Many of these recent advances have not yet been incorporated in the currently available guidelines, allowing for disparities in the treatment of patients with BRAFv-ATC across the US. With the increasing complexity in the management of BRAFv-ATC, this Consensus Statement aims to formulate guiding recommendations from a group of experts to facilitate therapeutic decision-making.This Consensus Statement from the FAST (Facilitating Anaplastic Thyroid Cancer Specialized Treatment) group at MD Anderson Cancer Center emphasizes that rapid identification of a BRAF V600E pathogenic variant and timely initiation of sequential therapy are critical to avoid excess morbidity and mortality in patients with BRAFv-ATC. In the past decade, remarkable progress has been made in the treatment of patients with BRAFv-ATC, justifying these new evidence-based recommendations reached through a consensus of experts from a high-volume center.